Efficient Human Breast Cancer Xenograft Regression after a Single Treatment with a Novel Liposomal Formulation of Epirubicin Prepared Using the EDTA Ion Gradient Method
Liposomes act as efficient drug carriers. Recently, epirubicin (EPI) formulation was developed using a novel EDTA ion gradient method for drug encapsulation. This formulation displayed very good stability and drug retention in vitro in a two-year long-term stability experiment. The cryo-TEM images show drug precipitate structures different than ones formed with ammonium sulfate method, which is usually used to encapsulate anthracyclines. Its pharmacokinetic properties and its efficacy in the human breast MDA-MB-231 cancer xenograft model were also determined. The liposomal EPI formulation is eliminated slowly with an AUC of 7.6487, while the free drug has an AUC of only 0.0097. The formulation also had a much higher overall antitumor efficacy than the free drug.
References
[1]
Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, et al. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987–992.
[2]
Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, et al. (1997) Long-circulating liposomes for drug delivery in cancer therapy: A review of biodistribution studies in tumor-bearing animals. Advanced Drug Delivery Reviews 24: 337–344. doi: 10.1016/s0169-409x(96)00476-0
[3]
Gabizon AA (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52: 891–896.
[4]
Gabizon AA (1994) Liposomal Anthracyclines. New Drug Therapy 8: 431–450.
[5]
Cern A, Golbraikh A, Sedykh A, Tropsha A, Barenholz Y, et al. (2012) Quantitative structure - property relationship modeling of remote liposome loading of drugs. Journal of Controlled Release 160: 147–157. doi: 10.1016/j.jconrel.2011.11.029
[6]
Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox RAK, et al. (2002) Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochimica Et Biophysica Acta-Biomembranes 1561: 188–201. doi: 10.1016/s0005-2736(02)00345-0
[7]
Zucker D, Marcus D, Barenholz Y, Goldblum A (2009) Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties. Journal of Controlled Release 139: 73–80. doi: 10.1016/j.jconrel.2009.05.036
[8]
Stathopoulos GP, Rigatos SK, Stathopoulos J (2010) Liposomal Cisplatin Dose Escalation for Determining the Maximum Tolerated Dose and Dose-limiting Toxicity: A Phase I Study. Anticancer Research 30: 1317–1321.
[9]
Lohr M, Graeven U, Bodoky G, Maerten A, Lilla C, et al. (2009) Cationic liposomal paclitaxel in combination with gemcitabine in patients with unresectable pancreatic cancer: a randomized controlled phase ii trial. Annals of Oncology 20: 9–9. doi: 10.1093/annonc/mdr379
[10]
Banno B, Ickenstein LM, Chiu GNC, Bally MB, Thewalt J, et al. (2010) The Functional Roles of Poly(Ethylene Glycol)-Lipid and Lysolipid in the Drug Retention and Release from Lysolipid-Containing Thermosensitive Liposomes In Vitro and In Vivo. Journal of Pharmaceutical Sciences 99: 2295–2308. doi: 10.1002/jps.21988
[11]
Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, et al. (2010) Phase II study of liposomal cisplatin (Lipoplatin (TM)) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 68: 240–247. doi: 10.1016/j.lungcan.2009.06.017
[12]
Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J (2006) Liposomal oxaliplatin in the treatment of advanced cancer: A phase I study. Anticancer Research 26: 1489–1493.
[13]
Tian W, Ying X, Du J, Guo J, Men Y, et al. (2010) Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. European Journal of Pharmaceutical Sciences 41: 232–243. doi: 10.1016/j.ejps.2010.06.008
[14]
Birtle AJ (2000) Anthracyclines and cardiotoxicity. Clinical Oncology 12: 146–152. doi: 10.1053/clon.2000.9141
[15]
Tidefelt U, Sundmanengberg B, Paul C (1991) Intracellular uptake and cytotoxic effect invitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic-cells. Cancer Chemotherapy and Pharmacology 29: 7–12. doi: 10.1007/bf00686328
[16]
Todorov DK, Ninjo SS, Zeller WJ (1995) Antiproliferative activity of liposomal epirubicin on experimental human gliomas in-vitro and in-vivo after intratumoral interstitial application. Journal of Cancer Research and Clinical Oncology 121: 164–168. doi: 10.1007/bf01198098
[17]
Mayhew EG, Lasic D, Babbar S, Martin FJ (1992) Pharmacokinetics and antitumor-activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. International Journal of Cancer 51: 302–309. doi: 10.1002/ijc.2910510221
[18]
Lipka D, Gubernator J, Filipczak N, Barnert S, Suss R, et al. (2013) Vitamin C-driven epirubicin loading into liposomes. Int J Nanomedicine 8: 3573–3585. doi: 10.2147/ijn.s47745
[19]
Gubernator J, Chwastek G, Korycinska M, Stasiuk M, Grynkiewicz G, et al. (2010) The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. Journal of Controlled Release 146: 68–75. doi: 10.1016/j.jconrel.2010.05.021
[20]
Koning GA, Eggermont AMM, Lindner LH, ten Hagen TLM (2010) Hyperthermia and Thermosensitive Liposomes for Improved Delivery of Chemotherapeutic Drugs to Solid Tumors. Pharmaceutical Research 27: 1750–1754. doi: 10.1007/s11095-010-0154-2
[21]
Laginha KM, Verwoert S, Charrois GJR, Allen TM (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clinical Cancer Research 11: 6944–6949. doi: 10.1158/1078-0432.ccr-05-0343
[22]
Stewart JCM (1980) Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Analytical Biochemistry 104: 10–14. doi: 10.1016/0003-2697(80)90269-9
[23]
Ickenstein LM, Arfvidsson MC, Needham D, Mayer LD, Edwards K (2003) Disc formation in cholesterol-free liposomes during phase transition. Biochimica Et Biophysica Acta-Biomembranes 1614: 135–138. doi: 10.1016/s0005-2736(03)00196-2
[24]
Riviere JE, Papich MG (2009) Veterinary Pharmacology and Therapeutics: Wiley-Blackwell.
[25]
Johnston MJW, Edwards K, Karlsson G, Cullis PR (2008) Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. Journal of Liposome Research 18: 145–157. doi: 10.1080/08982100802129372
[26]
Johnston MJW, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, et al. (2006) Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochimica Et Biophysica Acta-Biomembranes 1758: 55–64. doi: 10.1016/j.bbamem.2006.01.009
[27]
Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T (2000) Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy and Pharmacology 46: 459–466. doi: 10.1007/s002800000178
[28]
Popovic Z, Liu W, Chauhan VP, Lee J, Wong C, et al. (2010) A Nanoparticle Size Series for In Vivo Fluorescence Imaging. Angewandte Chemie-International Edition 49: 8649–8652. doi: 10.1002/anie.201003142
